Malcolm Gillies

IdMos Plc engages in research, development and commercialization of its disease detection and monitoring technology. The company is headquartered in Dundee, the United Kingdom.

Trading Emissions Plc operates as a closed-end investment company. The firm engages in business of investing in environmental and emissions assets; and companies providing products and services related to the reduction of greenhouse gas emissions and associated financial products. It operates through the following segments: Carbon, Private Equity, and Corporate. The Carbon segment deals with carbon investments and carbon related trade. The Private Equity segment consists of financial assets at fair value through profit or loss-private equity. The Corporate segment covers all assets and liabilities not otherwise attributable to the Carbon or Private Equity segments. The company was founded on March 15, 2005 and is headquartered in Douglas, Isle of Man.

Aircraft Medical Ltd. develops and produces medical devices that focus on the needs of anesthesia and critical care professionals. It offers video scope, video laryngoscope, medical device, laryngoscope, difficult intubation, camera stick, airway management and difficult airway management. The company was founded by Matthew John Ross McGrath in June 2001 and is headquartered in Edinburgh, the United Kingdom.

Axis-Shield Ltd. operates as a biotechnology company. The company was founded 1993 and is headquartered in the United Kingdom.

Shepherd & Wedderburn LLP provides legal services. The firm provides services to public Sector, rural, real estate and Infrastructure, food and drink and financial institution and banking sectors. The company was founded in 1922 and is headquartered in Edinburgh, the United Kingdom.

NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom.

Antoxis Ltd. designs and develops synthesis therapeutic antioxidants. The firm also develops innovative approaches for the treatment of neurodegenerative conditions, cardiovascular disease, cancer and inflammatory disorders through its mitochondrial-targeted, redox technology platform. The company was founded by Andrew Scott Johnstone and Donald Barton Mcphail in March 2005 and is headquartered in Aberdeen, the United Kingdom.

Recyclatech Group Ltd. develops a unique patented devulcanisation technology. The private company is based in Edinburgh, UK.